Search - tctmd.com

Displaying 241 - 260 of 453

Sort: Relevancy | Date

News Daily News

Grieving a Loved One Increases Mortality Risk in HF Patients

L.A. McKeown

July 06, 2022

News Opinion CV Team Dispatch

July 2022 News Roundup

L.A. McKeown

July 01, 2022

News Opinion Off Script

To Save a Dying Mother

Kathryn J. Lindley, MD

June 28, 2022

News Features

As US Abortion Protections Are Lost, Cardiologists Brace for Impact

Todd Neale

June 24, 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Conference News HRS 2022

Evidence Grows for Conduction-System Pacing as an Alternative to CRT

Todd Neale

May 05, 2022

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Caitlin E. Cox

May 03, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2022

Shelley Wood

May 02, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

Presentation ACC 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Presenter: Florian Rader

April 04, 2022

Presentation ACC 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presenter: Milind Y Desai

April 03, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

SODIUM-HF: No Impact of Dietary Salt Restriction on Death or Hospitalization

News Conference News ACC 2022

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

L.A. McKeown

April 02, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Daily News

Prognosis of Myocarditis Following COVID-19 Vaccination ‘Favorable’

Michael O'Riordan

March 28, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Daily News

AI-Based Tool IDs Hypertrophic Cardiomyopathy and Cardiac Amyloidosis

Yael L. Maxwell

February 24, 2022

News Daily News

Familial Patterns of Idiopathic Dilated Cardiomyopathy Becoming Clearer

L.A. McKeown

February 10, 2022

Advertisement

Grieving a Loved One Increases Mortality Risk in HF Patients

July 2022 News Roundup

To Save a Dying Mother

As US Abortion Protections Are Lost, Cardiologists Brace for Impact

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Dapagliflozin Boosts Health Status Across LVEF Range

Evidence Grows for Conduction-System Pacing as an Alternative to CRT

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

TCTMD’s Top 10 Most Popular Stories for April 2022

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Prognosis of Myocarditis Following COVID-19 Vaccination ‘Favorable’

What’s Going to Be Hot at ACC 2022, In Person or Virtual

AI-Based Tool IDs Hypertrophic Cardiomyopathy and Cardiac Amyloidosis

Familial Patterns of Idiopathic Dilated Cardiomyopathy Becoming Clearer

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content